CD8A and neoplasm: Preclinical studies have shown that the combination of α-Gr1 and α-Ly6C antibodies targeting PMN-MDSCs and M-MDSCs in cisplatin-resistant bladder cancer cells significantly reduced tumor volume and increased the infiltration of CD8+ T cells [77].